Oct. 23, 2012

TD-1211 Demonstrates Improvement in Bowel Movement Frequency and Bristol Stool Scores in a Phase 2b Study of Patients with Opioid-Induced Constipation (OIC)


TD-1211 for Opioid-Induced Constipation:
Theravance-discovered, multivalent, µ-opioid receptor neutral antagonist
Peripherally selective
Designed to normalize bowel movement frequency and quality
Once daily oral dosing

Dr. Webster is a consultant to Theravance for the TD-1211 development program. In the last 12 months, Dr. Webster has received Honoraria / Travel Support from the following
Covidien Mallinckrodt
Nektar Therapeutics
Salix Pharmaceuticals

Theravance, Inc., is investigating TD-1211 as a potential new treatment option for OIC.

Download PDF